Spots Global Cancer Trial Database for trastuzumab emtansine
Every month we try and update this database with for trastuzumab emtansine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 | Metastatic Brea... | paclitaxel pertuzumab [Per... trastuzumab emt... paclitaxel trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors | NCT02999672 | Bladder Cancer Pancreas Cancer Cholangiocellul... | Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy | NCT01419197 | Breast Cancer | Trastuzumab emt... Treatment of ph... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | NCT04298918 | Breast Cancer | Placebo Venetoclax Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | NCT04419181 | HER2-positive B... | Docetaxel Carboplatin Trastuzumab Pertuzumab Trastuzumab emt... | 18 Years - | University of Rochester | |
| A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | NCT01702571 | Breast Cancer | Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | NCT02236000 | Breast Cancer | Neratinib T-DM1 | 18 Years - | NSABP Foundation Inc | |
| A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | NCT01966471 | Breast Cancer | Trastuzumab Emt... Trastuzumab Pertuzumab Paclitaxel Epirubicin Doxorubicin Docetaxel Cyclophosphamid... 5-Fluorouracil | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane | NCT02658734 | HER2 Positive B... | Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC | NCT03784599 | Carcinoma, Non-... | Trastuzumab emt... Osimertinib | 18 Years - | The Netherlands Cancer Institute | |
| Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | NCT06125834 | Advanced Breast... Objective Respo... Trastuzumab Emt... | Trastuzumab Emt... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy | NCT02924883 | Metastatic Brea... | Atezolizumab Trastuzumab emt... Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer | NCT05415215 | Early Breast Ca... Locally Advance... Inflammatory Br... | Fixed Dose Comb... Pertuzumab IV Trastuzumab IV Trastuzumab Emt... Investigator's ... Surgery Radiotherapy | 18 Years - | Hoffmann-La Roche | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | NCT02390427 | Metastatic Brea... Recurrent Breas... | Taselisib Trastuzumab emt... Pertuzumab Trastuzumab Paclitaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | NCT06324357 | Metastatic Brea... Metastatic Gast... Gastroesophagea... Esophageal Aden... | Zongertinib Trastuzumab der... Trastuzumab emt... | 18 Years - | Boehringer Ingelheim | |
| T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | NCT01853748 | Breast Cancer | Trastuzumab Paclitaxel Trastuzumab emt... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer | NCT02144012 | Metastatic Brea... | Trastuzumab Trastuzumab Emt... Docetaxel | 18 Years - | Hoffmann-La Roche | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer | NCT05408845 | Metastatic Sali... Recurrent Saliv... Stage III Major... Stage IV Major ... Unresectable Sa... | Docetaxel Questionnaire A... Trastuzumab Trastuzumab Emt... | 18 Years - | NRG Oncology | |
| A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | NCT00934856 | Breast Cancer | Docetaxel Pertuzumab Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | NCT04351230 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Prognostic Stag... | Abemaciclib Trastuzumab Emt... | 18 Years - | Academic and Community Cancer Research United | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer | NCT06299852 | HER2-positive M... Oligometastatic... | Trastuzumab emt... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer | NCT01120561 | Metastatic Brea... | trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | NCT04439110 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trastuzumab Emt... | 18 Years - | National Cancer Institute (NCI) | |
| Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | NCT03894007 | Early-stage Bre... HER2-positive B... | Docetaxel Carboplatin Trastuzumab Pertuzumab Epirubicin Cyclophosphamid... Atezolizumab Trastuzumab emt... Paclitaxel | 18 Years - | Karolinska University Hospital | |
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | NCT06126640 | HER2-Positive P... | SHR-A1811 Trastuzumab Emt... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | NCT04622319 | HER2-Positive P... Residual Invasi... | DS-8201a T-DM1 | 18 Years - | Daiichi Sankyo | |
| A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors | NCT02999672 | Bladder Cancer Pancreas Cancer Cholangiocellul... | Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer | NCT00679211 | Metastatic Brea... | Trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | NCT01853748 | Breast Cancer | Trastuzumab Paclitaxel Trastuzumab emt... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | NCT00509769 | Metastatic Brea... | Trastuzumab emt... | - | Genentech, Inc. | |
| A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | NCT01120184 | Breast Cancer | docetaxel paclitaxel pertuzumab pertuzumab-plac... trastuzumab [He... trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | NCT04042051 | HER2-positive B... Metastatic Brea... Locally Advance... Unresectable Br... | Copanlisib Trastuzumab emt... | 18 Years - | Cancer Trials Ireland | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | NCT04457596 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Positive B... Invasive Breast... Multifocal Brea... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Synchronous Bil... | Trastuzumab Emt... Placebo Adminis... Tucatinib Questionnaire A... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | NCT06126640 | HER2-Positive P... | SHR-A1811 Trastuzumab Emt... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | NCT04931342 | Ovarian Cancer | Ipatasertib Cobimetinib Trastuzumab Emt... Atezolizumab Bevacizumab Paclitaxel Giredestrant Abemaciclib Inavolisib Palbociclib Letrozole Olaparib Luteinizing Hor... Cyclophosphamid... Inavolisib | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | NCT00829166 | Breast Cancer | Trastuzumab emt... Lapatinib Capecitabine | 18 Years - | Hoffmann-La Roche | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression | NCT00943670 | Metastatic Brea... | pertuzumab Trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer | NCT01120561 | Metastatic Brea... | trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | NCT02605915 | HER2-Positive M... HER2-Negative M... Locally Advance... | Atezolizumab Carboplatin Docetaxel Pertuzumab Trastuzumab Trastuzumab emt... Doxorubicin Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. | NCT03418558 | Metastatic Colo... | Trastuzumab emt... | 18 Years - | Fondazione del Piemonte per l'Oncologia | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | NCT03726879 | Breast Cancer | Atezolizumab Placebo Doxorubicin Cyclophosphamid... Paclitaxel Trastuzumab Pertuzumab Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | NCT04266249 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Docetaxel Lumpectomy Mastectomy Nab-paclitaxel Paclitaxel Pertuzumab Radiation Thera... Trastuzumab Trastuzumab Emt... | 18 Years - | Eastern Cooperative Oncology Group | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | NCT04266249 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Docetaxel Lumpectomy Mastectomy Nab-paclitaxel Paclitaxel Pertuzumab Radiation Thera... Trastuzumab Trastuzumab Emt... | 18 Years - | Eastern Cooperative Oncology Group | |
| Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine | NCT03025711 | Breast Neoplasm... | 18 Years - 100 Years | Puerta de Hierro University Hospital | ||
| Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) | NCT05735392 | Metastatic Brea... | Both blood and ... | 18 Years - | Consorzio Oncotech | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade | NCT04675827 | HER2-positive B... ER-Negative Bre... PR-Negative Bre... Node-negative B... | Pertuzumab and ... Trastuzumab emt... | 18 Years - | Jules Bordet Institute | |
| A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | NCT02131064 | Breast Neoplasm... | Carboplatin Docetaxel Pertuzumab Trastuzumab Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy | NCT05754502 | Breast Cancer | Trastuzumab emt... | 18 Years - | Consorzio Oncotech | |
| SMMART Adaptive Clinical Treatment (ACT) Trial | NCT05238831 | Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre... | Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib | 18 Years - | OHSU Knight Cancer Institute | |
| A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer | NCT05945927 | Breast Cancer | Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | NCT01513083 | Breast Cancer | trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | NCT05673928 | Metastatic Soli... Brain Metastase... | Trastuzumab emt... Tucatinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | NCT06126640 | HER2-Positive P... | SHR-A1811 Trastuzumab Emt... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen | NCT00932373 | Metastatic Brea... | trastuzumab-MCC... | - | Genentech, Inc. | |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen | NCT00932373 | Metastatic Brea... | trastuzumab-MCC... | - | Genentech, Inc. | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | NCT04457596 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Positive B... Invasive Breast... Multifocal Brea... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Synchronous Bil... | Trastuzumab Emt... Placebo Adminis... Tucatinib Questionnaire A... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors | NCT02999672 | Bladder Cancer Pancreas Cancer Cholangiocellul... | Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | NCT02131064 | Breast Neoplasm... | Carboplatin Docetaxel Pertuzumab Trastuzumab Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | NCT01120184 | Breast Cancer | docetaxel paclitaxel pertuzumab pertuzumab-plac... trastuzumab [He... trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | NCT03726879 | Breast Cancer | Atezolizumab Placebo Doxorubicin Cyclophosphamid... Paclitaxel Trastuzumab Pertuzumab Trastuzumab Emt... | 18 Years - | Hoffmann-La Roche | |
| Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction | NCT04680442 | Breast Cancer Heart Failure | Trastuzumab Pertuzumab Trastuzumab emt... | - | Population Health Research Institute | |
| Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction | NCT04680442 | Breast Cancer Heart Failure | Trastuzumab Pertuzumab Trastuzumab emt... | - | Population Health Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
